CoChat
Sign Up
Cited by 119Genetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesSexual Differentiation and DisordersEstrogen and related hormone effects

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Conjugated Oral versus Transdermal Estrogen Replacement in Girls with Turner Syndrome: A Pilot Comparative Study

Nabhan, Zeina M., DiMeglio, Linda A., Qi, Rong, Perkins, Susan M., Eugster, Erica A.·2009·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2008-2123
Open this paper in CoChat — free account

Abstract

BACKGROUND: The optimal route of estrogen replacement in Turner syndrome (TS) is unknown. OBJECTIVE: The objective of the study was to compare conjugated oral vs. transdermal estrogen (TD E2) on bone accrual, uterine growth, pubertal development, IGF-I, and lipids in girls with TS. METHODS: Prepubertal GH-treated girls aged 10 yr or older with TS were eligible. Subjects were randomized to conjugated oral estrogen or TD E2 for 1 yr. Assessments included dual-emission x-ray absorptiometry, pelvic ultrasound, Tanner staging, growth velocity, IGF-I, and lipid profile. RESULTS: Twelve girls (14.0 +/- 1.7 yr) were enrolled. TD E2 resulted in a significantly greater change in spine bone density at 12 months compared with conjugated oral estrogen (bone mineral content 9.0 +/- 0.9 vs. 5.8 +/- 0.9 g, P = 0.04; bone mineral density 0.12 +/- 0.01 vs. 0.06 +/- 0.01 g/cm2, P = 0.004; Z-score 0.7 +/- 0.1 vs. 0.3 +/- 0.1, P = 0.03). Greater increases in uterine length (4.13 +/- 0.39 vs. 1.98 +/- 0.39 cm, P = 0.003) and volume (22.2 +/- 4.4 vs. 4.0 +/- 4.4 ml, P = 0.02) were also found in the TD vs. the oral group at 1 yr. At study end, 66% of subjects in the TD group had a mature uterus vs. 0% in the oral group. No significant differences in other parameters examined were seen. CONCLUSION: In girls with TS, TD E2 resulted in faster bone accrual at the spine and increased uterine growth compared with conjugated oral estrogen. This pilot study provides preliminary information for optimizing estrogen replacement in this population.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2008-2123

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

Sorted by citations

See all 119

Related

Metadata

Authors
Nabhan, Z. M., DiMeglio, L. A., Qi, R., Perkins, S. M., & Eugster, E. A.
Affiliations
  • Indiana University Hospital (US)
  • Indiana University Indianapolis (US)
  • Riley Hospital for Children (US)
Corresponding author
Nabhan, Zeina M.
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2009-06-01
Volume
94
Issue
6
Pages
2009-2014
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2008-2123
OpenAlex
W2120922659
Cited by
119
References
37
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 3 · 2020: 6 · 2019: 15 · 2018: 6 · 2017: 9 · 2016: 5 · 2015: 8 · 2014: 12 · 2013: 9 · 2012: 4
FWCI
4.84
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
Turner syndrome, estrogen replacement therapy, transdermal estrogen, bone mineral accrual, uterine growth, pubertal development, insulin-like growth factor I, lipid profile
MeSH terms
Administration, Cutaneous, Administration, Oral, Adolescent, Body Composition, Bone Development, Child, Estrogens, Conjugated (USP), Female, Humans, Insulin-Like Growth Factor I, Lipids, Pilot Projects, Puberty, Turner Syndrome, Uterus, Bone Density, Estrogen Replacement Therapy, Adolescent Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review